A Saga University research team is aiming to start in summer of this year at the earliest a clinical study involving the transplantation of blood vessels made with a three-dimensional bioprinter (see below) into patients receiving hemodialysis.
The group, which is driven by organ recovery scientist Prof. Koichi Nakayama of the college, has presented an application to start the investigation to a making a decision about advisory group assigned by the focal government.
The transplantation of body tissues delivered by a 3-D bioprinter is believed to be unprecedented on the planet.
Bioprinters can deliver three-dimensional body tissue. In regular regenerative medication, transplantation includes singular cells and sheet-formed body tissue. It is trusted that 3-D bioprinters will almost certainly produce tissues and organs with increasingly confused shapes, propelling the field of regenerative drug.
In the investigation plan, a 3-D bioprinter created by Nakayama, Tokyo-based medicinal gear start-up Cyfuse Biomedical K.K. furthermore, others will be utilized.
Scientists will develop skin cells to create cell pieces that will end up being the crude material for the produced tissue.
The researchers then thread the cell chunks onto thin, long needles lined like pin holders in accordance with 3-D data of blood vessels.
The cells stick together within several days, forming blood vessels about five centimeters long and six millimeters in diameter after the pins have been removed.
The researchers will transplant the produced blood vessels into three to five patients receiving hemodialysis.
If shunts, or resin pipes to remove blood from the body, are inserted into patients’ arms for a long period of time, the inside of the shunts become clogged and the blood does not flow smoothly.
The researchers aim to improve the flow by replacing the shunts with blood vessels.
The team will examine the safety and effectiveness of the method for six months.
Nakayama said: “Blood vessels made from patients’ own cells have no rejection and are less likely to cause infectious diseases compared to shunts.
The cells are scheduled to be processed in a facility in Gamagori, Aichi Prefecture. The clinical study is supported by the Japan Agency for Medical Research and Development.
The device automatically layers cells based on digital data and makes three-dimensional tissue. While conventional 3-D printers make objects using plastic as source material, 3-D bioprinters use a mixture of cells and collagen or liquid containing cells.